What Should Be Done To Tackle Ghostwriting in the Medical Literature?

被引:63
|
作者
Gotzsche, Peter C. [1 ]
Kassirer, Jerome P. [2 ]
Woolley, Karen L. [3 ,4 ]
Wager, Elizabeth
Jacobs, Adam [5 ]
Gertel, Art
Hamilton, Cindy
机构
[1] Nord Cochrane Ctr, Copenhagen, Denmark
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Univ Queensland, Brisbane, Qld 4072, Australia
[4] ProScribe Med Commun, Noosaville, Qld, Australia
[5] Dianthus Med Ltd, London, England
来源
PLOS MEDICINE | 2009年 / 6卷 / 02期
关键词
PEER-REVIEWED PUBLICATIONS; PHARMACEUTICAL COMPANIES; AUTHORSHIP; PREVALENCE; HONORARY; JOURNALS; WRITERS; TRIALS;
D O I
10.1371/journal.pmed.1000023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background to the debate: Ghostwriting occurs when someone makes substantial contributions to a manuscript without attribution or disclosure. It is considered bad publication practice in the medical sciences, and some argue it is scientific misconduct. At its extreme, medical ghostwriting involves pharmaceutical companies hiring professional writers to produce papers promoting their products but hiding those contributions and instead naming academic physicians or scientists as the authors. To improve transparency, many editors' associations and journals allow professional medical writers to contribute to the writing of papers without being listed as authors provided their role is acknowledged. This debate examines how best to tackle ghostwriting in the medical literature from the perspectives of a researcher, an editor, and the professional medical writer.
引用
收藏
页码:122 / 125
页数:4
相关论文
共 50 条